Fundraising FoxMyokardia
Unicorn exit · $13.1Bacquired by Bristol Myers SquibbSouth San Francisco, US · Founded 2012 · Delaware corporation · 4 known investors
Find your way into Myokardia
Sign up to see every warm intro you have to Myokardia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Myokardia team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Bristol Myers Squibb November 2020 · $13.1B ($13.1 billion, or $225.00 per share in cash) · source ↗
MyoKardia was a clinical-stage biopharmaceutical company using precision medicine and genomics to develop targeted small-molecule treatments for genetic cardiovascular diseases, including the drug mavacamten for hypertrophic cardiomyopathy.
Founders & leadership
Board
Investors · 4
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Khosla Ventures's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$56M disclosed across 2 rounds · 2014–2015
▶$46MraisedApr 2015 · 9 investors · BiotechnologyRule 506(b)
- Kevin StarrDirector
- Charles HomcyDirector
- Mark PerryDirector
- Katherine BowdishDirector
- Tassos Anastasios GianakakosExecutive Officer, Director
- Offering amount
- $46M
- Amount sold
- $46M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$10MraisedAug 2014 · 1 investors · BiotechnologyRule 506(b)
- Tassos Anastasios GianakakosExecutive Officer, Director
- Charles HomcyDirector
- Kevin StarrDirector
- Mark PerryDirector
- Katherine BowdishDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Myokardia went on to found or lead other companies.
Frequently asked questions
- What does Myokardia do?
- MyoKardia was a clinical-stage biopharmaceutical company using precision medicine and genomics to develop targeted small-molecule treatments for genetic cardiovascular diseases, including the drug mavacamten for hypertrophic cardiomyopathy.
- Who are Myokardia's investors?
- Myokardia's investors include Avoro Capital Advisors, Foresite Capital, Khosla Ventures, Third Rock Ventures.
- How much funding has Myokardia raised?
- Myokardia has disclosed $56M raised across 2 rounds.
- Who acquired Myokardia?
- Myokardia was acquired by Bristol Myers Squibb.
- Where is Myokardia headquartered?
- Myokardia is headquartered in South San Francisco, US.